Teva Sells Off Remaining Women’s Health Assets For $1.4B

Law360, New York (September 18, 2017, 6:43 PM EDT) -- Teva Pharmaceutical Industries Ltd. said Monday it will sell the remainder of its global women’s health portfolio in a pair of transactions totaling nearly $1.4 billion as the company turns its focus toward central nervous system and respiratory medicines.

New York-based private equity fund CVC Capital Partners Fund VI will pay $703 million in an all-cash transaction to pick up a portfolio consisting of a variety of women’s health products from Israel-based Teva. The drugs include contraceptives Seasonique and Zoely, menopause medication Colpotrophine, fertility treatment Ovaleap, and osteoporosis medicine Actonel.

Teva also announced a deal with Pennsylvania-based, over-the-counter medication company Foundation...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS